compani
preview diabet net price
focu anim health updat
forecast revenu vs prior con y/i driven
trulic basaglar new product taltz verzenio slightli
conserv street key new product launch includ taltz vs
con olumi vs verzenio vs
non-gaap ep estim con assum y/i op margin expans
om line mid-point management guidanc base recent market
trend took trulic estim increas po
unchang methodolog reiter neutral rate see limit room
upsid est necessari justifi re-rat
focu area call
topic includ follow trulic growth outlook categori growth
remain strong share us non-insulin market translat
y/i categori growth help valid long-term trulic growth
drug held nrx share vs despit competitor nvo
ozemp launch howev net us sale import gaug net price
encourag nvo comment ada didnt want overpay get
access earli product like ozemp due long-term potenti suggest us
nvo remain ration price two-competitor market new product
launch taltz psoriasi follow miss broadli across drug
elanco strateg updat previous announc would provid updat
strateg direct anim health busi elanco ep call given
sale announc believ elanco spin-out possibl outcom
report pre-g oper margin estim annual
ebitda assum increment sale stand-alon would like
trade low end anim health comp due revenu growth profil
last om forecast ep contribut total
separ announc spin sale compani may provid updat
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
timestamp juli edtcr eli lilli compani
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani juli
biopharmaceut compani
diversifi therapeut focu product
focus treat diseas condit
diabet cancer immunolog central nervou
system disord deep pipelin drug
therapeut focu mirror commerci
portfolio found
incorpor indiana top sell
product includ humalog sale
ciali alimta forteo
one highest ep growth name among
us major pharma new product launch
cost cut measur expect drive
neutral believ stock beat
street estim achiev multipl expans
given competit payer headwind
compani diabet categori
risk new brand launch disappoint consensu
verzenio taltz set tough bogey
net interest incom
mn except
compani juli
compani
price object po base blend averag discount
cash flow dcf target multipl appli ep dcf assum
wacc termin growth price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-
upsid risk po better-than-anticip margin expans on-going
cost-cut program verzenio show meaning clinic differenti
result signific uptak
downsid risk po slower growth trulic rapid biosimilar eros
humalog franchis slower growth new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
compani juli
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani juli
